ER-positive/HER2-positive breast cancers are more prone to form bone metastases, instead of ER-negative/HER-2 positive ones which manifest a higher propensity to visceral organs including the brain, lung, and liver (37). This evidence concerns the gene ERBB2 and breast cancer.